LET Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about LET clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 383 trials

Recruiting
Phase 1

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure SyndromeFamilial Platelet Disorder With Predisposition to Myeloid Malignancies
National Cancer Institute (NCI)75 enrolled1 locationNCT06090669
Recruiting
Phase 1Phase 2

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

MTAP-deleted Solid Tumors
Servier Bio-Innovation LLC342 enrolled35 locationsNCT06188702
Recruiting

Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions

Von Willebrand DiseasesMajor Constitutional ThrombopathyPatient on Antiplatelet Drugs
Centre Hospitalier Universitaire Dijon200 enrolled2 locationsNCT03773159
Recruiting
Not Applicable

Cancer Genetic Testing in Ethnic Populations

Breast CarcinomaHead and Neck CarcinomaMalignant Brain Neoplasm+8 more
Mayo Clinic1,800 enrolled2 locationsNCT04475640
Recruiting

Musculoskeletal Disorders of Postgraduate Dentistry Students and Specialist Dentists

Musculoskeletal DiseasesWork-related Injury
Abant Izzet Baysal University90 enrolled1 locationNCT07088965
Recruiting
Not Applicable

Virtual Reality (VR) Self-Hypnosis Software

Musculoskeletal PainNeuropathic PainNeuralgia
Icahn School of Medicine at Mount Sinai25 enrolled1 locationNCT06398847
Recruiting
Not Applicable

Pain in Aging Former Athletes, Master's Athletes, and Nonathletes

PainExercise TrainingPain Management+4 more
Marquette University90 enrolled1 locationNCT07502742
Recruiting
Phase 2

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital74 enrolled1 locationNCT07505173
Recruiting
Not Applicable

Relationship Between Modality-specific Dual-task Performance and Immersive Exergaming Outcomes in Healthy Athletes

Healthy Athlete
Zurich University of Applied Sciences60 enrolled1 locationNCT07461025
Recruiting

Intraoperative Laxity Assessment of ACL Reconstruction, ACL Revision and MAT

Intraoperative Musculoskeletal Injury
Istituto Ortopedico Rizzoli1,500 enrolled1 locationNCT03441165
Recruiting
Not Applicable

Bone Stimulator for Spondylolysis

AthletesSpondylolysisSymptomatic Spondylolysis
The Methodist Hospital Research Institute48 enrolled1 locationNCT06666608
Recruiting
Phase 3

Canadian Critical Care Comparative Effectiveness Platform

NutritionVasopressorIntensive Care Unit ICU+1 more
Université de Sherbrooke5,500 enrolled8 locationsNCT06605144
Recruiting

Adherence to Home-Based Exercises in Musculoskeletal Disorders

Musculoskeletal DiseaseExercise TrainingStroke+6 more
Konya Beyhekim Training and Research Hospital252 enrolled1 locationNCT07261553
Recruiting
Not Applicable

RGL-305+ Lymphoma + Exploratory Clinical Study

Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
Fudan University12 enrolled1 locationNCT07006012
Recruiting

The effect of standardised pathway on the diagnosis and management of platelet-related bleeding disorders.

Inherited abnormalities in platelet number or platelet function.
Northern Sydney Local Health District350 enrolled1 locationACTRN12626000342314
Recruiting
Phase 2

Platelet Rich Plasma Injections In Young And Old Human Subjects

OsteoarthritisMusculoskeletal DisordersArticular Cartilage
University of California, San Francisco60 enrolled1 locationNCT06451120
Recruiting

Natural History of Inflammatory Muscle Diseases

Inflammation In Skeletal Muscle
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)500 enrolled1 locationNCT05738824
Recruiting
Not Applicable

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

EBV-associated T/NK-cell Lymphoproliferative DiseasesRefractory/Relapsed EBV-related Hemophagocytic LymphohistiocytosisLetermovir
Beijing Children's Hospital80 enrolled1 locationNCT07488728
Recruiting
Not Applicable

Multisite Transspinal Stimulation for Augmenting Recovery in Spinal Cord Injury

Spinal Cord Injuries (Complete and Incomplete)
Maria Knikou, PT, MBA, PhD36 enrolled1 locationNCT07204184
Recruiting
Phase 2Phase 3

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled262 locationsNCT07063745